Last reviewed · How we verify
NCT03857568
A Trial of SHR0410 Injection in Hemodialysis Participants.
Phase 1 trial testing SHR0410 in Pruritus in 8 participants. Completed in 8 November 2019.
8 November 2019
Quick facts
| Lead sponsor | Atridia Pty Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 15 April 2019 |
| Primary completion | 8 November 2019 |
| Estimated completion | 8 November 2019 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- SHR0410
- Placebo
Conditions studied
- Pruritus — all drugs for Pruritus →
Sponsor
Atridia Pty Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Pruritus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-site study to evaluate the safety and pharmacokinetics of repeated doses of IV SHR0410 in participants who are undergoing hemodialysis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A New Generation of Treatments for Itch.
Fowler E, Yosipovitch G. · · 2020 · cited 30× · PMID 31940047 · DOI 10.2340/00015555-3347
Verify or expand the search:
- PubMed search for NCT03857568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SHR0410
Trials testing the same drug.
- NCT04099927 — A Study of SHR4010 in Patients With Hemodialysis · Phase 1 · completed
Other recruiting trials for Pruritus
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT06751056 — Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch · NA · recruiting
- NCT06800755 — Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque · NA · recruiting
- NCT06787794 — Reducing Itch With Hypnosis and Virtual Reality · NA · recruiting
- NCT06488742 — The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis · NA · recruiting
Other Atridia Pty Ltd. trials
Trials by the same sponsor.
- NCT07358377 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negati · Phase 1 · not yet recruiting
- NCT07390747 — A Trial of SHR-2173 in Healthy Volunteers · Phase 1 · recruiting
- NCT07238647 — A Trial of HRS-5817 in Obese Participants · EARLY_PHASE1 · recruiting
- NCT07078695 — A Trial of SHR-1139 in Healthy Volunteers · Phase 1 · active not recruiting
- NCT07033455 — A Trial of HRS-1893 in Healthy Volunteers · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03857568 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atridia Pty Ltd.
- Last refreshed: 10 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03857568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing